Hydroxychloroquine in pregnant patients with systemic lupus erythematosus

Journal of Rheumatology

Volumn 23, Issue 10, 1996, Pages 1715-1718

  Parke, Ann ^a   West, Bruno ^a  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

antimalarial drugs; antiphospholipid antibody syndrome; pregnancy; systemic lupus erythematosus

Indexed keywords

HEPARIN; HYDROXYCHLOROQUINE; PREDNISONE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG SAFETY; FEMALE; FETUS; FETUS OUTCOME; HUMAN; NEWBORN; ORAL DRUG ADMINISTRATION; PREGNANCY; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANTIMALARIALS; CHILD, PRESCHOOL; FEMALE; FETUS; FOLLOW-UP STUDIES; HEARING DISORDERS; HUMANS; HYDROXYCHLOROQUINE; INFANT; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY OUTCOME; PRENATAL EXPOSURE DELAYED EFFECTS; VISION DISORDERS;

EID: 0029825260     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Rudnicki RD, Gresham GE, Rothfield NF: The efficacy of antimalarials in systemic lupus erythematosus. J Rheumatol 1975;2:323-30.
2. Buchanan RN Jr: Quinacrine in the treatment of discoid lupus erythematosus. A five year follow-up survey: Results and evaluation. South Med J 1959;52:978-83.
3. Dubois EL: Antimalarials in the management of discoid and systemic lupus erythematosus. Semin Arthritis Rheum 1978;8:33-51.
4. The Canadian Hydroxychloroquine Study Group: A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. N Engl J Med 1991;324:150-4.
5. The Canadian Hydroxychloroquine Study Group: Preliminary results of a longterm study of hydroxychloroquine (HCQ) withdrawal on major exacerbations in SLE. Lupus 1995;(suppl 2):4:98.
6. Bertrand E, Cloitre B, Ticolat R, et al.: Antiaggregation action of chloroquine. Med Trop (Mars) 1990;50:143-6.
7. Wallace DJ, Metzger AL, Stecher VJ, et al.: Cholesterol-lowering effect of hydroxychloroquine (Plaquenil) in rheumatic disease patients. Reversal of deleterious effects of steroids on lipids. Am J Med 1990;89:322-6.
8. Jonsson H, Nived O, Sturfelt G: Outcome in systemic lupus erythematosus: A prospective study of patients from a defined population. Medicine (Baltimore) 1989;68:141-50.
9. Petri M, Lakatta C, Magder L, et al.: The effect of prednisone and hydroxychloroquine on coronary artery disease risk factors in SLE: A longitudinal study (abstr). Arthritis Rheum 1992;35:S54.
10. Petri M, Hochberg M, Hellmann D, et al.: Incidence of and predictors of thrombotic events in SLE: Protective role of hydroxychloroquine (abstr). Arthritis Rheum 1992;35:S53.
11. Nasr S, Larson D, Parke A: Long term oral anticoagulants are not necessary to prevent recurrent thrombotic episodes in all patients with phospholipid antibodies. (Submitted for publication.)
12. Parke AL, Ernst L, Salafia C: Placental pathology in the phospholipid antibody syndrome and SLE. Am J Obstet Gynecol: In press.
13. Briggs GG, Freeman RK, Yaffe SJ: Drugs in Pregnancy and Lactation. Baltimore: Williams & Wilkins, 1990.
14. Roubenoff R, Hoyt J, Hochberg MC, Hellmann DB: Effects of antiinflammatory and immunosuppressive drugs on pregnancy and fertility. Semin Arthritis Rheum 1988;18:88-110.
15. Wolfe MJ, Cordero JF: Safety of chloroquine in chemosuppression of malaria during pregnancy. BMJ 1985;290:1466-7.
16. Ullberg S, Lindquist NJ, Sjostrand SE: Accumulation of chorioretinotoxic drugs in the fetal eye. Nature 1970;227:1257-8.
17. Henkind P, Rothfield NF: Ocular abnormalities in patients treated with synthetic antimalarial drugs. N Engl J Med 1963;269:433-9.
18. Bernstein HN: Ophthalmologic considerations and testing in patients receiving longterm antimalarial therapy. Am J Med 1983;75 (suppl 1a):25-34.
19. Grundmann M, Rihová D, Lukásová D, Vrublovský P: Tissue distribution of chloroquine and hydroxychloroquine in the rat. Acta Univ Palacki Olomuc Fac Med 1982;102:99-105.
20. Hart CN, Naunton RF: The ototoxicity of chloroquine phosphate. Arch Otolaryngol Head Neck Surg 1964;80:407-12.
21. Ross JB, Garatos S: Absence of chloroquine-induced ototoxicity in a fetus (letter). Arch Dermatol 1974;109:573.
22. Fraga A, Mintz G, Orozco J, et al.: Sterility and fertility rates, fetal wastage and maternal morbidity in systemic lupus erythematosus. J Rheumatol 1974;1:293-8.
23. Tozman ECS, Urowitz MB, Gladman DD: Systemic lupus erythematosus and pregnancy. J Rheumatol 1980;7:621-32.
24. Lockshin MD, Druzin ML, Goei S, et al.: Antibodies to cardiolipin as a predictor of death in pregnant patients with systemic lupus erythematosus. N Engl J Med 1985;313:152-6.
25. Parke AL, Wilson D, Maier D: The prevalence of antiphospholipid antibodies in women with recurrent spontaneous abortion, women with successful pregnancies, and women who have never been pregnant. Arthritis Rheum 1991;34:1231-5.
26. Zurier RB, Argyros TG, Urman JD, et al.: SLE management during pregnancy. Obstet Gynecol 1977;51:178-80.
27. Gimovsky HC, Monotoro M, Paul RH: Pregnancy outcome in women with systemic lupus erythematosus. Obstet Gynecol 1984;63:686-92.
28. Tett SE, Cutler DJ, Day RO, Brown KF: Bioavailability of hydroxychloroquine tablets in healthy volunteers. Br J Clin Pharmacol 1989;27:771-9.
29. Parke AL: Antimalarial drugs, systemic lupus erythematosus and pregnancy. J Rheumatol 1988;15:607-10.
30. Toubi E, Buchanan NMM, Khamashta MA, Lima F, Kerslake K, Hughes GRV: The safety of hydroxychloroquine in lupus pregnancy: Experience in 27 pregnancies. Lupus 1995;(suppl 2):4:118.
31. MacKenzie AH: Antimalarial drugs for rheumatoid arthritis (Oral Gold Symposium). Am J Med 1983;75:48-58.
32. McChesney EW: Animal toxicity and pharmacokinetics of hydroxychloroquine sulfate. Am J Med 1983;75:11-5.
33. McChesney EW, Banks WF Jr, Sullivan DJ: Metabolism of chloroquine and hydroxychloroquine in albino and pigmented rats. Toxicol Appl Pharmacol 1965;1:625-36.
34. Finbloom DS, Silver K, Newsome DA, Gunkel R: Comparison of hydroxychloroquine and chloroquine use and the development of retinal toxicity. J Rheumatol 1985;12:692-4.
35. Johnson MW, Vine AK: Hydroxychloroquine therapy in massive total doses without retinal toxicity. Am J Ophthalmol 1987;104:139-44.
36. Levy M, Buskila D, Gladman DD, Urowitz MB, Koren G: Pregnancy outcome following first trimester exposure to chloroquine. Am J Perinatol 1991;8:174-8.